| Title |
Drug sensitivity patterns of HHV8 carrying body cavity lymphoma cell lines
|
|---|---|
| Published in |
BMC Cancer, October 2011
|
| DOI | 10.1186/1471-2407-11-441 |
| Pubmed ID | |
| Authors |
Rita Ötvös, Henriette Skribek, Lorand L Kis, Annunziata Gloghini, Laszlo Markasz, Emilie Flaberg, Staffan Eksborg, Jozsef Konya, Lajos Gergely, Antonino Carbone, Laszlo Szekely |
| Abstract |
Primary effusion lymphoma (PEL) is a rare KSHV/HHV8-associated high-grade non-Hodgkin's lymphoma (NHL) of B-cell origin, characterized by serous effusions in body cavities. Most patients are HIV-infected men with severe immunosuppression and other HHV8-associated diseases such as Kaposi's sarcoma (KS). The prognosis for those infected is poor, with a median survival of less than 6 months in most cohorts. Sustained complete remission is rare. High-dose chemotherapy regimens are used to improve remission rate and survival. The aim of the present study was to compare the drug sensitivity pattern of the available primary effusion (body cavity based) lymphoma-derived cell lines in order to find additional, potentially effective drugs that are not included in current chemotherapy treatment protocols. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 46 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 13% |
| Student > Bachelor | 2 | 4% |
| Student > Doctoral Student | 2 | 4% |
| Student > Ph. D. Student | 2 | 4% |
| Professor | 1 | 2% |
| Other | 0 | 0% |
| Unknown | 33 | 72% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 4 | 9% |
| Psychology | 3 | 7% |
| Biochemistry, Genetics and Molecular Biology | 2 | 4% |
| Agricultural and Biological Sciences | 2 | 4% |
| Unknown | 35 | 76% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 October 2011.
All research outputs
#20,147,309
of 22,653,392 outputs
Outputs from BMC Cancer
#6,476
of 8,237 outputs
Outputs of similar age
#125,000
of 135,954 outputs
Outputs of similar age from BMC Cancer
#64
of 87 outputs
Altmetric has tracked 22,653,392 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,237 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 135,954 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 87 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.